Testing of diagnosis with a therapeutic trial: Concept and requirements for a therapeutic trial

European Journal of Gastroenterology and Hepatology

Volumn 13, Issue SUPPL. 3, 2001, Pages

  Fass, R ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; ANTACID AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROGESTERONE; PROKINETIC AGENT; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SEDATIVE AGENT; SEROTONIN 4 AGONIST; THEOPHYLLINE DERIVATIVE; TRANQUILIZER;

ANTIREFLUX OPERATION; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HEARTBURN; HELICOBACTER PYLORI; HUMAN; LIFESTYLE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; SIDE EFFECT; STOMACH ACID SECRETION; STOMACH PH; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0035200830     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (81)

1. Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastroesophageal reflux disease
2. The functional gastrointestinal disorders
3. Esophageal hypersensitivity: A major cause of heartburn?
4. Analysis of multiphasic radiographic examination for detecting reflux esophagitis
5. An evidence-based appraisal of reflux disease management - The Genval Workshop Report
6. Ancillary tests in the diagnosis of gastroesophageal reflux disease
7. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain
8. Omeprazole as a diagnostic tool in gastroesophageal reflux disease
9. Empirical trials in treatment of gastroesophageal reflux disease
10. Empiric therapy for gastroesophageal reflux disease
11. One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease
12. Omeprazole administration as a test for gastroesophageal reflux disease
13. Single dose omeprazole as a test for noncardiac chest pain
14. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease
15. Pilot study of the oral omeprazole test for reflux laryngitis
16. Prospective, double-blind study comparing omeprazole 40mg bid vs. placebo in patients with chronic cough and GE reflux
17. Omeprazole test for gastroesophageal reflux-related chronic persistent cough
18. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis
19. The endoscopic assessment of esophagitis: A progress report on observer agreement
20. Endoscopic assessment of oesophagitis: Clinical and functional correlates and further validation of the Los Angeles classification
21. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression
22. Appropriate acid suppression for the management of gastro-oesophageal reflux disease
23. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease
24. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects
25. max of esomeprazole on acid secretion and intragastric pH
26. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease
27. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastro-esophageal reflux disease
28. Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg
29. Esomeprazole 40 mg provides more effective acid control than pantoprazole 40 mg
30. Esomeprazole 40 mg provides more effective acid control than rabeprazole 20 mg
31. Heartburn - The acid test
32. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis
33. Rationale and efficacy of conservative therapy for gastroesophageal reflux disease
34. Effects of sleeping with the bed-head raised and of ranitidine in patients with severe peptic oesophagitis
35. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - A placebo-controlled randomized trial
36. The effect of body position on lower esophageal sphincter pressure
37. Evaluation of elevation of the head of the bed, bethanechol, and antacid foam tablets on gastroesophageal reflux
38. The time pattern of gastroesophageal reflux
39. Gastric distention: A mechanism for postprandial gastroesophageal reflux
40. Does massive obesity promote abnormal gastroesophageal reflux?
41. A comparison of high and low fat meals on postprandial esophageal acid exposure
42. Relative stimulatory effects of commonly ingested beverages on gastric acid secretion in humans
43. Ethanol-induced acute esophageal motor dysfunction
44. Mechanisms of acid reflux associated with cigarette smoking
45. Gastroesophageal reflux induced by exercise in healthy volunteers
46. Drug therapy for reflux oesophagitis
47. Ranitidine therapy for gastroesophageal reflux disease: Results of a large double-blind trial
48. Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled dose-ranging study
49. Treatment of erosive reflux oesophagitis: A double-blind multicentre trial with nizatidine 300mg b.i.d. versus placebo
50. Ranitidine for erosive esophagitis: A double-blind, placebo-controlled study
51. Comparison of omeprazole and cimetidine in reflux oesophagitis: Symptomatic, endoscopic, and histological evaluations
52. Omeprazole produces significantly greater healing of erosive or ulcerative reflux oesophagitis than ranitidine
53. Cost effectiveness of treatment for gastro-oesophageal reflux diseases in clinical practice: A clinical database analysis
54. Acute treatment of reflux oesophagitis: A multicentre trial to compare 150 mg ranitidine b.d. with 300 mg ranitidine q.d.s.
55. Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis
56. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease
57. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice
58. Ranitidine is effective therapy for erosive esophagitis
59. Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer
60. H. pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease
61. Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors
62. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial
63. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial
64. Comparison of the new PPI esomeprazole, the S-isomer of omeprazole, vs placebo for the treatment of symptomatic GERD
65. Medical therapy. Management of the refractory patient
66. Long-term treatment with omeprazole for refractory reflux esophagitis: Efficacy and safety
67. Factors predicting relapse of GERD after antireflux surgery and during medical treatment. Results of a randomised multi-center trial
68. Persistent acid secretion during omeprazole therapy: A study of gastric acid profiles in patients demonstrating failure of omeprazole therapy
69. Combined gastric and oesophageal 24-hour pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazole
70. Oesophageal motility defects associated with nocturnal gastro-oesophageal reflux on proton pump inhibitors
71. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux - The 'sensitive oesophagus'
72. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: Evidence for a spectrum of visceral sensitivity in GORD
73. Functional esophageal disorders
74. Acid perception in gastro-oesophageal reflux disease is dependent on psychosocial factors
75. 24-Hour pH monitoring in symptomatic patients without erosive esophagitis who did not respond to antireflux treatment
76. Does 40 mg omeprazole daily offer additional benefit over 20 mg daily in patients requiring more than 4 weeks of treatment for symptomatic reflux oesophagitis?
77. Gastro-oesophageal reflux associated with nocturnal acid breakthrough on proton pump inhibitors
78. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily
79. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects
80. Bedtime ranitidine does not eliminate the need for a second daily dose of omeprazole to suppress nocturnal gastric pH
81. Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms: Testing while on therapy identifies the need for more aggressive anti-reflux therapy